Skip to main content

Extendryl PSE Side Effects

Generic name: methscopolamine / pseudoephedrine

Note: This document provides detailed information about Extendryl PSE.

Applies to methscopolamine/pseudoephedrine: oral tablet extended release Side Effects associated with methscopolamine / pseudoephedrine. Some dosage forms listed on this page may not apply specifically to the brand name Extendryl PSE.

Applies to methscopolamine/pseudoephedrine: oral tablet extended release.

Cardiovascular

Cardiovascular side effects have included cardiac palpitations. In general, sympathomimetics have been associated with tachycardia, arrhythmias, and cardiovascular collapse with hypotension.[Ref]

Nervous system

Nervous system side effects have included drowsiness, lassitude, increased irritability and excitement (especially in children). Other side effects associated with sympathomimetic amines have included headache, dizziness, anxiety, fear, nervousness, restlessness, tremor, weakness, insomnia, hallucinations, convulsions, and CNS depression.

Antihistamines and anticholinergic drugs side effects have included drowsiness and dizziness.[Ref]

Gastrointestinal

Gastrointestinal side effects have included nausea and excessive dryness of the mouth, nose and throat.[Ref]

Ocular

Ocular side effects have included blurred vision.[Ref]

Genitourinary

Genitourinary side effects associated with the used of sympathomimetic amines have included dysuria and urinary retention in patients with prostatic hypertrophy.[Ref]

Respiratory

Respiratory side effects associated with the use of sympathomimetics have included respiratory difficulty.[Ref]

References

1. (2002) "Product Information. PSE 120/MSC 2.5 (methscopolamine-pseudoephedrine)." Cypress Pharmaceutical Inc

Further information

Extendryl PSE side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.